ClinicalTrials.gg
CompletedNCT04103905Updated May 18, 2025

A Study of MIL62 in Treatment of CD20 Positive B-cell Lymphomas

A Phase 1 interventional study of Recombinant Humanized Monoclonal Antibody MIL62 Injection in CD20-positive B Cell Non-Hodgkin Lymphoma, sponsored by Beijing Mabworks Biotech Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-18.

Sponsored by Beijing Mabworks Biotech Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 7 months after the study started (first participant enrolled Feb 2017, registered Sep 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This open-label, multicenter,dose-escalating phase I study was designed to evaluate the safety, tolerability, pharmacokinetics and efficacy of MIL62 in Chinese patients with relapsed/refractory CD20-positive B-cell non-Hodgkin lymphoma(NHL) for whom no treatment of higher priority was available.

02

Conditions studied

  • CD20-positive B Cell Non-Hodgkin Lymphoma
03

In context

Lead sponsor

Beijing Mabworks Biotech Co., Ltd. is the lead sponsor of 18 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult patients, >=18 years of age;
  2. Diagnosis of /relapsed CD20+ B-cell lymphoma or B-CLL
  3. (ECOG) performance status of 0 or 1
  4. >6 months
  5. Females of (FCBP) must agree to use two reliable forms of simultaneously or to practice complete abstinence from heterosexual contact during the following time periods related to this study: 1) for at least 28 days before starting study drug; 2) while participating in the study; 3) dose interruptions; and 4) for at least 2 months after discontinuation of all study treatments
  6. Able and willing to provide written and to comply with the study protocol

Exclusion criteria

Exclusion Criteria:

  1. Prior use of any antibody therapy within 3 months of study start
  2. Prior use of any anti-cancer vaccine
  3. Prior administration of radioimmunotherapy 3 months prior to study entry
  4. Central nervous system lymphoma
  5. History of other
  6. Evidence of significant, uncontrolled concomitant disease
  7. Abnormal laboratory values
  8. Patients with progressive multifocalleukoencephalopathy (PML)
  9. Infection with (HIV), or (including HBsAg,HBcAb positive with abnormal HBV DAN or HCV RNA )
  10. Known severe allergic reaction or/and infusion reaction to monoclonal antibody.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    MIL62

    Drug: Recombinant Humanized Monoclonal Antibody MIL62 Injection

Interventions

  • The patients confirming to the eligibility criteria will be assigned to the 5 dose groups (200mg, 400mg, 800mg, 1000mg, and 1500mg, respectively) based on the sequence of inclusion. Each patient received an intravenous infusion of MIL62 on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 10 infusions. Each cycle was 21 days.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Experienced a Dose-limiting Toxicity in Dose Escalation Period of the Study

    Time frame: Baseline to 28 days after the first infusion of MIL62 of the last participant in dose escalation period

Secondary outcomes

  1. Percentage of Participants With Best Overall Response

    Time frame: by the end of Cycle 8 (each cycle is 28 days)

  2. Maximum Observed Plasma Concentration (Cmax) Under Steady State of MIL62

    Time frame: by the end of Cycle 4 (each cycle is 28 days)

  3. Area Under the Plasma Concentration Versus Time Curve (AUC) of MIL62 Under Steady State

    Time frame: by the end of Cycle 4 (each cycle is 28 days)

  4. Systemic Clearance of MIL62 Under Steady State

    Time frame: by the end of Cycle 4 (each cycle is 28 days)

  5. Volume of Distribution Under Steady State (Vss) of MIL62

    Time frame: by the end of Cycle 4 (each cycle is 28 days)

  6. Terminal Plasma Half-Life (t1/2) of MIL62 Under Steady State

    Time frame: by the end of Cycle 4 (each cycle is 28 days)

  7. Change in Cluster of Differentiation 19 (CD19+) B Cells

    Time frame: by the end of Cycle 4 (each cycle is 28 days)

  8. Change in Cluster of Differentiation 20 (CD20+) B Cells

    Time frame: by the end of Cycle 4 (each cycle is 28 days)

  9. Percentage of Participants with Positive Anti-Drug Antibodies to MIL62

    Time frame: by the end of Cycle 4 (each cycle is 28 days)

  10. Progression-free Survival (PFS) in the Study

    Time frame: by the end of the follow-up period of the study

  11. Overall Survival (OS) in the Study

    Time frame: by the end of the follow-up period of the study

  12. Duration of response (DoR)

    Time frame: by the end of the follow-up period of the study

  13. Disease control rate (DCR)

    Time frame: by the end of the follow-up period of the study

  14. Participants With Event-Free Survival (EFS)

    Time frame: by the end of the follow-up period of the study

07

Study locations

1 site
  • Chinese Academy of Medical Sciences (CAMS) & Peking Union Medical College (PUMC)
    Beijing, Beijing 100021, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2017 to primary completion in May 2019, 27 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2019
First posted
Sep 26, 2019
StartActual
Feb 10, 2017
Primary completionActual
May 30, 2019
CompletionActual
May 29, 2020
Last update
May 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04103905
Lead sponsor
Beijing Mabworks Biotech Co., Ltd.
Responsible party
Sponsor
First posted
Sep 26, 2019
Start date
Feb 10, 2017
Primary completion
May 30, 2019
Completion
May 29, 2020
Last update
May 18, 2025

Study contacts

Yuankai Shi
principal investigator · Chinese Academy of Medical Sciences (CAMS) & Peking Union Medical College (PUMC)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-CD20 Monoclonal Antibody MIL62

Start the discussion